Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00048555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma
Study identification
- NCT ID
- NCT00048555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- IDEC-114 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2002
- Primary completion
- Feb 29, 2004
- Completion
- Oct 31, 2010
- Last update posted
- Sep 15, 2013
2002 – 2010
United States locations
- U.S. sites
- 22
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research site | Birmingham | Alabama | 35294 | — |
| Research site | Tucson | Arizona | 85724 | — |
| Research site | Los Angeles | California | 90095 | — |
| Research site | Newport Beach | California | 92658 | — |
| Research site | San Diego | California | 92121 | — |
| Research site | Aurora | Colorado | 80010 | — |
| Research site | Washington D.C. | District of Columbia | 20007 | — |
| Research site | Tampa Bay | Florida | 33612 | — |
| Research site | Chicago | Illinois | 60611 | — |
| Research site | Maywood | Illinois | 60153 | — |
| Research site | Boston | Massachusetts | 2115 | — |
| Research site | Detroit | Michigan | 48202 | — |
| Research site | Rochester | Minnesota | 55905 | — |
| Research site | Omaha | Nebraska | 68198 | — |
| Research site | Buffalo | New York | 14263 | — |
| Research site | New York | New York | 10021 | — |
| Research site | Rochester | New York | 14642 | — |
| Research site | Durham | North Carolina | 27710 | — |
| Research site | Philadelphia | Pennsylvania | 1906 | — |
| Research site | Columbia | South Carolina | 29210 | — |
| Research site | Houston | Texas | 77030 | — |
| Research site | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00048555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2013 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00048555 live on ClinicalTrials.gov.